Zealand Pharma Secures $100M Royalty Deal for Rusfertide
Event summary
- Zealand Pharma sells royalty rights for rusfertide to Royalty Pharma for $100M.
- $50M upfront payment with the remaining $50M due in one year.
- Zealand retains a 0.25% royalty on sales exceeding $1.5B, while Royalty Pharma gets 0.75%.
- Rusfertide's NDA review by FDA set for Q3 2026 with Takeda handling global commercialization.
The big picture
Zealand Pharma's deal with Royalty Pharma converts a future royalty stream into immediate capital, aligning with its strategic focus on metabolic health innovations. The transaction underscores the growing trend of biotech firms monetizing non-core assets to fund core growth initiatives. With rusfertide's regulatory review pending and Takeda managing commercialization, Zealand aims to leverage this financial boost for its long-term pipeline ambitions.
What we're watching
- Regulatory Milestones
- The FDA's PDUFA goal date for rusfertide in Q3 2026 will determine the timeline for potential market entry.
- Capital Redeployment
- How Zealand Pharma allocates the $100M to advance its Metabolic Frontier 2030 strategy and obesity pipeline.
- Commercial Performance
- The pace at which rusfertide achieves sales exceeding $1.5B, triggering higher royalty payments for Zealand Pharma.
Related topics